Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 29, 2026 1 hour, 46 minutes ago
Medical News: A fascinating new study suggests that common antibiotics may hold unexpected promise in the fight against leukemia, one of the most serious blood cancers. Researchers have discovered that certain modified antibiotics can actively kill leukemia cells by triggering internal “self-destruct” mechanisms, offering a potential new direction for cancer treatment.
Modified antibiotics show promise in targeting leukemia cells through multiple death pathways
Repurposing Old Drugs for New Battles
Scientists from Suez Canal University (Egypt), Karolinska Institutet (Sweden), Karolinska University Hospital, and the University of Zakho (Iraq) explored whether well-known tetracycline antibiotics could be repurposed as cancer-fighting agents. Their focus was on three compounds: doxycycline, minocycline, and a chemically modified version called COL-3.
Drug repurposing is gaining attention globally because it allows researchers to use medications that are already proven safe, potentially speeding up the development of new therapies. In this case, the team wanted to see whether these antibiotics could interfere with key survival pathways inside leukemia cells.
How the Study Was Conducted
The researchers tested the drugs on three different types of leukemia cells: K562, KG-1a, and Jurkat. Each represents a different subtype of leukemia, allowing scientists to observe how the drugs behave across various disease forms.
Using laboratory techniques, they measured how effectively each compound reduced cell survival and whether the cells died through apoptosis, a natural process where damaged or unwanted cells self-destruct.
COL-3 Emerges as the Most Powerful Compound
The findings revealed that all three compounds reduced leukemia cell survival, but one stood out clearly. COL-3 showed the strongest cancer-killing ability across all cell types tested.
In fact, Jurkat cells were especially sensitive, with even small doses of COL-3 significantly reducing their survival. According to the data presented in the study, COL-3 consistently required much lower concentrations to achieve the same effect compared to doxycycline and minocycline .
This suggests that slight chemical modifications to existing drugs can dramatically improve their effectiveness against cancer.
Triggering Cancer Cell Suicide
The most important discovery was how these drugs actually kill leukemia cells. Instead of causing random damage, they trigger apoptosis, a controlled and cleaner form of cell death.
The study showed that:
In some leukemia types, the drugs worked independently of major signaling pathways.
In others, especially Jurkat cells, they directly interfered with the JAK2/STAT3 pathway, a key system that cancer cells use to survive and grow.
This
Medical News report highlights t
hat when this pathway was blocked, cancer cells became far more likely to die, especially when paired with reduced levels of BCL-2, a protein that normally helps cells avoid death.
Different Leukemia Types Respond Differently
Interestingly, not all leukemia cells reacted the same way. Some relied heavily on the JAK/STAT pathway, while others were more influenced by internal mitochondrial processes involving proteins like BAX and BCL-2.
This variation shows why leukemia is such a complex disease and why treatments often need to be tailored to specific subtypes.
Real-World Challenges Still Remain
Despite the promising results, the researchers caution that not all findings can be directly applied to patients yet. Some of the drug concentrations used in the lab were higher than what is typically achievable in the human body.
However, COL-3 appears more realistic for clinical use, as its effective doses were closer to levels that could potentially be reached in patients.
Conclusion
The study provides compelling evidence that tetracycline-based compounds, especially COL-3, could be repurposed as anti-leukemia agents. By targeting multiple pathways and triggering programmed cell death, these drugs show a dual-action effect that could be highly valuable in future treatments. While more research is needed, particularly in human trials, the findings open the door to innovative therapies using familiar and widely available medications. This could significantly reduce development time and costs while offering new hope to leukemia patients worldwide.
The study findings were published in the peer reviewed journal: Pharmaceutics.
https://www.mdpi.com/1999-4923/18/4/415
For the latest on using antibiotic compounds to treat cancer, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/cancer
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
